RGLS-8429 is under clinical development by Regulus Therapeutics and currently in Phase I for Polycystic Kidney Disease. According to GlobalData, Phase I drugs for Polycystic Kidney Disease have a 69% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how RGLS-8429’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

RGLS-8429 overview

RGLS-8429 is under development for the treatment of autosomal dominant polycystic kidney disease (ADPKD). The therapeutic candidate acts by targeting microRNA-17 (miR-17). It is being developed based on microRNA platform technology. The platform involves single-stranded oligonucleotides which regulate the expression of genes. It is administered through subcutaneous route.

Regulus Therapeutics overview

Regulus Therapeutics (Regulus) is a biopharmaceutical company that focuses on the discovery and development of microRNA-based therapeutics for orphan kidney diseases such as autosomal dominant polycystic kidney diseases. It is investigating RG-012 which is a chemically modified oligonucleotide that inhibits the function of miR-21 for the treatment of Alport syndrome and RGLS8429 targeting autosomal dominant polycystic kidney disease (ADPKD). The company is also evaluating therapies against infectious diseases and central nervous system disorders. It utilizes its proprietary microRNA development platform to discover and develop its therapies for cancer, fibrosis, metabolic and inflammatory disorders. Regulus Therapeutics is headquartered in San Diego, California, the US.

For a complete picture of RGLS-8429’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.